Nyembo Philippe F, Buda Kevin G, Hooker Abel, Ayenew Woubeshet
Internal Medicine, Hennepin Healthcare, Minneapolis, USA.
Cardiology, Hennepin Healthcare, Minneapolis, USA.
Cureus. 2022 Apr 9;14(4):e23979. doi: 10.7759/cureus.23979. eCollection 2022 Apr.
Management of mechanical prosthetic valve thrombosis (PVT) includes medical and surgical options. Standard medical treatment involves thrombolytic therapy with repeated slow infusions of low-dose IV tissue plasminogen activator (t-PA). The evidence for managing mechanical PVT that does not respond to the standard t-PA dosing is limited in the setting of an exacerbating hypercoagulable condition. We present a case of a patient with a history of antiphospholipid syndrome who presented with a probable thromboembolic myocardial infarction secondary to a mechanical mitral valve thrombosis that did not improve with systemic anticoagulation and repeated standard t-PA dosing but rapidly resolved with ultraslow, high-dose t-PA.
机械性人工瓣膜血栓形成(PVT)的管理包括药物和手术选择。标准药物治疗包括使用低剂量静脉组织纤溶酶原激活剂(t-PA)反复缓慢输注进行溶栓治疗。在高凝状态加重的情况下,对于对标准t-PA剂量无反应的机械性PVT的管理证据有限。我们报告一例有抗磷脂综合征病史的患者,该患者因机械性二尖瓣血栓形成继发可能的血栓栓塞性心肌梗死,全身抗凝和反复标准t-PA给药均未改善,但超慢速、高剂量t-PA治疗后迅速缓解。